Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T16:48:06.115Z.
Consensus retrieved: 2026-10-06T13:33:00.462Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T16:48:06.115Z.
Quote observation: 2026-10-06T16:45:05.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 4b39d0c73cbdfa69f0b7c8f40e573a317b01c7cc2fd28b7d8d8bae27d2fbb310
Forward PE Ratio (N/A) = Dated Quote Price ($6.72) / Consensus Forward EPS ($0.01)
FORWARD PE RATIO
N/A
LENSAR Inc
Market Cap
$82.59M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| LENSAR Inc (LNSR) | $82.59M | N/A |
| MediciNova, Inc. (MNOV)vs › | $82.45M | N/A |
| Acrivon Therapeutics, Inc. Common Stock (ACRV)vs › | $82.82M | N/A |
| ProMIS Neurosciences, Inc. (PMN)vs › | $83.53M | N/A |
| Cardiff Oncology, Inc. (CRDF)vs › | $83.98M | N/A |
| Humacyte, Inc. (HUMA)vs › | $84.07M | N/A |
| Cognition Therapeutics, Inc. (CGTX)vs › | $84.24M | N/A |
| Nutriband Inc. (NTRB)vs › | $80.32M | 4.21 |
| Citius Oncology, Inc. (CTOR)vs › | $80.19M | 8.62 |
| Atara Biotherapeutics, Inc. (ATRA)vs › | $85.33M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $6.72, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $0.01 | $0.01 – $0.01 | 1 | 862.2x |
| 2027-12-31 | $-0.22 | $-0.24 – $-0.21 | 1 | n/m |
| 2028-12-31 | $0.02 | $-0.37 – $0.41 | 2 | 301.6x |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
